BTIG Research Forecasts Strong Price Appreciation for Personalis (NASDAQ:PSNL) Stock

Personalis (NASDAQ:PSNL) had its price objective boosted by equities researchers at BTIG Research from $12.00 to $13.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. BTIG Research’s target price would suggest a potential upside of 46.07% from the stock’s current price.

PSNL has been the subject of a number of other research reports. Morgan Stanley lifted their target price on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a report on Monday, December 1st. Lake Street Capital reiterated a “buy” rating and issued a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Guggenheim increased their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. HC Wainwright upped their price objective on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Personalis currently has an average rating of “Moderate Buy” and an average target price of $10.86.

Personalis Stock Up 3.2%

Shares of PSNL stock opened at $8.90 on Wednesday. The firm has a market cap of $790.32 million, a price-to-earnings ratio of -10.11 and a beta of 1.98. Personalis has a 12 month low of $2.83 and a 12 month high of $11.50. The stock has a 50-day moving average price of $8.92 and a 200 day moving average price of $7.70.

Insider Buying and Selling

In related news, CFO Aaron Tachibana sold 103,668 shares of the business’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the transaction, the chief financial officer directly owned 164,458 shares in the company, valued at approximately $1,772,857.24. The trade was a 38.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Personalis

Hedge funds and other institutional investors have recently bought and sold shares of the business. Deutsche Bank AG grew its holdings in Personalis by 4.5% in the 4th quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after buying an additional 1,655 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after acquiring an additional 2,395 shares in the last quarter. Howland Capital Management LLC grew its stake in shares of Personalis by 0.9% in the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after acquiring an additional 2,500 shares in the last quarter. Intech Investment Management LLC increased its position in Personalis by 23.4% during the fourth quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after acquiring an additional 3,851 shares during the period. Finally, International Assets Investment Management LLC acquired a new stake in Personalis in the 4th quarter worth about $31,000. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.